-
282022.01
SCM Life Science has completed recruiting patients with phase 2a clini..
SCM Life Science (SCM Life Science, 298060, CEO Sun Uk Song), a company specializing in research and development of cel..
-
282022.01
“SCM Life Science, Expectations for listing and clinical performance o..
On the 15th, Korea Investment & Securities expected full-scale disclosure of clinical results and technology trans..
-
282022.01
SCM Life Science “Results of phase 2 acute pancreatitis and atopic der..
"Next year is a year to prepare for the release of treatments in 2023. Based on the results of phase 2 clinical t..
-
282022.01
Drugs for atopic and acute pancreatitis to start exporting technology
Sun Uk Song, CEO of SCM Life Science, who recently returned to the forefront of management, met with a reporter on the ..
-
282022.01
SCM Life Science completed the initiation meeting for phase 2 clinical..
SCM Life Science (SCM Life Science, Kosdaq 298060, CEO Lee Byung-gun), a development company specializing in cell thera..
-
282022.01
SCM Life Science has obtained a U.S. patent for the composition of dru..
SCM Life Science (SCM Life Science, Kosdaq 298060, CEO Lee Byung-gun), a development company specializing in cell thera..
-
282022.01
SCM Life Science, Introduction of diabetes treatments from bio-venture..
SCM Life Science (CEO Lee Byung-gun), a development company specializing in cell therapy, announced on the 1st that it ..
-
282022.01
SCM Life Science, equity investment in U.S. bio-venture Vita Theraputi..
SCM Life Science (CEO Lee Byung-gun), a development company specializing in cell therapy, announced on the 30th that it..
-
282022.01
SCM Life Science, enters the global Cosmetic market... Bonotox Japan a..
SCM Life Science, a company specializing in cell therapy (Scm Life Science, CEO Lee Byung-gun. KOSDAQ 298060) announced..